Zymeworks to Attend Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 22, 2024 - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, is focused on developing a variety of innovative and multifunctional biotherapeutics aimed at enhancing care for challenging diseases.
Zymeworks recently announced its participation in several upcoming investor conferences. The company’s management team will engage in one-on-one meetings and fireside chats at the following events:
1. Wells Fargo Healthcare Conference: Scheduled for September 4 at 8:45 am Eastern Time (ET) in Boston, MA.
2. Morgan Stanley 22nd Annual Global Healthcare Conference: Set to take place on September 5 at 7:00 am ET in New York, NY.
3. H.C. Wainwright 26th Annual Global Investment Conference: Slated for September 10 at 11:00 am ET in New York, NY.
4. 2024 Cantor Global Healthcare Conference: Planned for September 18 at 3:05 pm ET in New York, NY.
About Zymeworks Inc.
Zymeworks Inc. is a global clinical-stage biotechnology firm dedicated to the discovery, development, and commercialization of novel biotherapeutics. The company's mission is to significantly impact the lives of individuals affected by challenging-to-treat cancers and other diseases. Zymeworks employs complementary therapeutic platforms and an integrated drug development engine to design and develop highly specialized antibody-based therapeutic candidates.
A notable achievement by Zymeworks is the development of zanidatamab, a HER2-targeted bispecific antibody engineered using the company's proprietary Azymetric™ technology. Zymeworks has established separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz) to develop and commercialize zanidatamab in various territories.
Zanidatamab is undergoing numerous global clinical trials to assess its potential as a best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA). Additionally, a BLA has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would become the first HER2-targeted therapy specifically approved for BTC in the U.S. and China.
Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in antibody-drug conjugates and multispecific antibody therapeutics targeting multiple novel areas with significant unmet medical needs. Beyond its own pipeline, the company’s therapeutic platforms are utilized in strategic partnerships with global biopharmaceutical companies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
